Qurcan Therapeutics Overview
- Year Founded
-
2018
- Status
-
Private
- Employees
-
5
- Latest Deal Type
-
Accelerator/Inc
- Investors
-
19
Qurcan Therapeutics General Information
Description
Developer of a non-viral drug delivery platform designed to provide genetic medicines for neurological diseases. The company's platform utilizes target-engineered responsive polymers, polymer-lipid nanoparticles, and dual-specific transport pathways to provide systemic CNS delivery, gene silencing, and genome editing, enabling pharmaceutical partners to transport therapeutic payloads across the blood-brain barrier for the treatment of genetic conditions.
Contact Information
Website
www.qurcan.comCorporate Office
- BioLabs Toronto, 661 University Avenue
- Suite 1300
- Toronto, Ontario M5G 0B7
- Canada
Corporate Office
- BioLabs Toronto, 661 University Avenue
- Suite 1300
- Toronto, Ontario M5G 0B7
- Canada
Qurcan Therapeutics Timeline
Qurcan Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 18. Accelerator/Incubator | Completed | Generating Revenue | ||||
| 17. Accelerator/Incubator | 29-May-2024 | Completed | Generating Revenue | |||
| 16. Later Stage VC | 01-Apr-2024 | Completed | Generating Revenue | |||
| 15. Accelerator/Incubator | 01-Nov-2023 | Completed | Pre-Clinical Trials | |||
| 14. Accelerator/Incubator | 25-Oct-2023 | Completed | Pre-Clinical Trials | |||
| 13. Accelerator/Incubator | 14-Oct-2022 | Completed | Pre-Clinical Trials | |||
| 12. Secondary Transaction - Private | 24-Jan-2022 | Completed | Pre-Clinical Trials | |||
| 11. Seed Round | 17-May-2021 | Completed | Pre-Clinical Trials | |||
| 10. Grant | 13-Jan-2020 | $225K | $2.24M | Completed | Pre-Clinical Trials | |
| 9. Seed Round | 18-Apr-2019 | $2.24M | $2.24M | Completed | Pre-Clinical Trials |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
Qurcan Therapeutics Comparisons
Industry
Financing
Details
Qurcan Therapeutics Competitors (2)
One of Qurcan Therapeutics’s 2 competitors is NuvOx Therapeutics, a Venture Capital-Backed company based in Tucson, AZ.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| NuvOx Therapeutics | Venture Capital-Backed | Tucson, AZ | ||||
| KORTUC | Venture Capital-Backed | Palo Alto, CA |
Qurcan Therapeutics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Qurcan Therapeutics Patents
Qurcan Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-4727588-A1 | Intelligent polymer-lipid based nano drug delivery system to improve the bbb-penetration by dual active brain targeting strategies | Pending | 15-Jun-2023 | ||
| WO-2024254703-A1 | Intelligent polymer-lipid based nano drug delivery system to improve the bbb-penetration by dual active brain targeting strategies | Inactive | 15-Jun-2023 | ||
| US-20260294830-A1 | An intelligent charge switchable polymer-lipid hybrid system for in vivo delivery of molecules including rnas | Pending | 03-Jun-2023 | ||
| WO-2024250095-A1 | An intelligent charge switchable polymer-lipid hybrid system for in vivo delivery of molecules including rnas | Inactive | 03-Jun-2023 | A61K9/5123 |
Qurcan Therapeutics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Qurcan Therapeutics Investors (19)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| BioTools Innovator | Accelerator/Incubator | Minority | ||
| MedTech Innovator | Accelerator/Incubator | |||
| CABHI | Corporate Venture Capital | Minority | ||
| McNamara Investments | Family Office | Minority | ||
| Federal Economic Development Agency for Southern Ontario | Government |
Qurcan Therapeutics FAQs
-
When was Qurcan Therapeutics founded?
Qurcan Therapeutics was founded in 2018.
-
Where is Qurcan Therapeutics headquartered?
Qurcan Therapeutics is headquartered in Toronto, Canada.
-
What is the size of Qurcan Therapeutics?
Qurcan Therapeutics has 5 total employees.
-
What industry is Qurcan Therapeutics in?
Qurcan Therapeutics’s primary industry is Drug Discovery.
-
Is Qurcan Therapeutics a private or public company?
Qurcan Therapeutics is a Private company.
-
What is Qurcan Therapeutics’s current revenue?
The current revenue for Qurcan Therapeutics is .
-
How much funding has Qurcan Therapeutics raised over time?
Qurcan Therapeutics has raised $5.09M.
-
Who are Qurcan Therapeutics’s investors?
BioTools Innovator, MedTech Innovator, CABHI, McNamara Investments, and Federal Economic Development Agency for Southern Ontario are 5 of 19 investors who have invested in Qurcan Therapeutics.
-
Who are Qurcan Therapeutics’s competitors?
NuvOx Therapeutics and KORTUC are competitors of Qurcan Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
